Q3 FY24 Quarterly Report and Appendix 4C: First Positive Operating Cash Flow Quarter Underpinned by Strong Financial and Operational Performance
Divesture of Non-US Assets for ~US$9.5M (~A$13.7M) Allowing for Payoff of A$8.2M Debt Facility while Funding Expansion of US Business
H1 FY24 Half Year Report and Appendix 4D: 29% Reduction in Net Cash Used in Operating Activities alongside Stable Revenue
life science investing Execution of Variation to Facility Agreement with PURE Asset Management, Company to Seek a Sale Transaction
life science investing Q4 FY23 Quarterly Report and Appendix 4C: Net Cash Used in Operating Activities Down 56% YoY to Record Low
